mResvia is a vaccine for protecting against lower respiratory tract disease (diseases of the lungs such as bronchitis and pneumonia) caused by respiratory syncytial virus (RSV) in adults aged 18 years and older. mResvia contains a molecule called messenger RNA (mRNA) with instructions for producing an RSV protein called membrane-anchored RSV-A glycoprotein F.
Therapeutic Indication
### Therapeutic indication mResvia is indicated for active immunisation for the prevention of lower respiratory tract disease (LRTD) caused by Respiratory Syncytial Virus (RSV) in adults 18 years of age and older. The use of this vaccine should be in accordance with official recommendations.
Therapeutic Area (MeSH)
ATC Code
J07BX05
ATC Item
respiratory syncytial virus vaccines
Pharmacotherapeutic Group
Vaccines
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| single-stranded 5' capped mRNA encoding the Respiratory syncytial virus glycoprotein F stabilized in the prefusion conformation | N/A | single-stranded 5' capped mrna encoding the respiratory syncytial virus glycoprotein f stabilized in the prefusion conformation |
| Respiratory syncytial virus mRNA vaccine (nucleoside modified) | N/A | respiratory syncytial virus mrna vaccine (nucleoside modified) |
| Single-stranded 5' capped mRNA encoding the Respiratory syncytial virus glycoprotein F stabilized in the prefusion conformation | N/A | single-stranded 5' capped mrna encoding the respiratory syncytial virus glycoprotein f stabilized in the prefusion conformation |
| Single-stranded 5' capped mRNA encoding the respiratory syncytial virus glycoprotein F stabilised in the prefusion conformation | N/A | single-stranded 5' capped mrna encoding the respiratory syncytial virus glycoprotein f stabilised in the prefusion conformation |
EMA Name
mResvia
Medicine Name
mResvia
Aliases
N/ANo risk management plan link.
